Biotalys Shares Surge 33% in a Week Following US Approval

EVOCA's Approval in Florida Propels the Stock Above Its Resistances

Today's catalyst is clearly identified: on Monday, April 27, 2026, Biotalys announced the registration of its biofungicide EVOCA in the state of Florida, marking the first authorization of a biocontrol based on its AGROBODY technology on American soil. This regulatory milestone paves the way for concrete commercialization in the strategic US market. Technically, Biotalys is now trading at €3.095, significantly surpassing the resistance identified at €2.96. The price also exceeds the upper limit of the Bollinger Bands, located at €3.07, signaling a potential overbought zone. Such configurations often occur during bullish accelerations fueled by fundamental events, but caution is advised if the stock fails to stabilize above this threshold. The 50-day moving average, at €2.91, has also been exceeded, confirming the short-term momentum.

Focus on Wednesday's Annual Results

Biotalys' financial calendar is drawing significant attention: annual results will be published on Wednesday, April 29, 2026, the very next session. This event comes at a time when the stock has already gained more than 33% in a week, while still down 2.37% year-over-year and 4.18% over three months. The 200-day moving average, at €4.14, remains well above the current price, highlighting that the underlying trend is still fragile despite the recent surge. Monthly volatility stands at 16.93, while the very low beta of 0.14 indicates a significant decoupling from major indices. During the session, the CAC 40 is up 0.27% at 8,164.19 points and the DAX is up 0.09% at 24,104.26 points, in a generally calm European environment. Biotalys' general assembly is also scheduled for May 29, 2026.